This phase I trial studies the side effects and best dose of fractionated stereotactic radiation therapy in treating patients with cancer that has spread to the brain and has not been removed by surgery. Fractionated stereotactic radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03726359.
Locations matching your search criteria
United States
New York
Bronx
Montefiore Medical Center-Weiler HospitalStatus: Active
Contact: Madhur K. Garg
Phone: 718-920-4140
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose of fractionated stereotactic radiation therapy (FSRT) in the treatment of brain metastases.
SECONDARY OBJECTIVES:
I. To determine the percentage of patients who have achieved a complete response, partial response, or stable disease in response to FSRT treatment.
TERTIARY OBJECTIVES:
I. To determine if molecular biomarkers in the blood circulation, prior to, during the course of treatment, and at the first follow up after treatment predicts overall survival.
OUTLINE: This is a dose-escalation study.
Patients undergo FSRT every other day (QOD) for 1.5-2 weeks.
After completion of study treatment, patients are followed up every 2 months in year 1, every 4 months in year 2, every 6 months in year 3, then annually thereafter.
Lead OrganizationMontefiore Medical Center-Weiler Hospital
Principal InvestigatorMadhur K. Garg
